Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV-1-infection: early-phase trial registry
24 of 72 indexed HIV-1-infection trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #191 of 28,707 conditions by registered trial count.
72 US clinical trials · 24 currently recruiting · #191 of 28,707 conditions by registered trial count
HIV-1-infection: 72 US clinical trials tracked, 24 recruiting.
HIV-1-infection is the subject of 72 registered US clinical trials on ClinicalTrials.gov, 24 of them currently open to new participants. 15 are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most active sponsor is Gilead Sciences, running 20 of these trials.
Enrollment posture brief
Registry condition hiv-1-infection
OPEN 24 | RECR 33% | LATE 15 | EARLY 40 | RANK #191 | SPON 20
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
HIV-1-infection lists 24 open slots (33% of 72 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HIV-1-infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HIV-1-infection is recruiting below its size-band peers.
24 of 72 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HIV-1-infection research.
Gilead Sciences accounts for 20 of 72 trials (27.8%). 35 distinct sponsors appear on at least one study for this condition label.
-
Typical HIV-1-infection enrolment sits around 80 participants.
Median target enrolment is 80 among the 72 trials that report a genuine target (sentinel values excluded). 40 of those (55.6%) plan for fewer than 100 participants.
-
HIV-1-infection research is mostly interventional.
62 interventional and 10 observational studies make up this index (86.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
72 total, page 2 of 2
Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen
Thomas Jefferson University
NCT03646370
Testing the Efficacy and Mechanisms of an Adapted Resilience Building Intervention in People Aging With HIV
University of Alabama at Birmingham
NCT05314088
A Mobile Intervention to Promote Cessation in HIV-infected Smokers
Montefiore Medical Center
NCT02432482
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NCT01351025
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NCT01903031
Acute Neural and Immune Effects of Alcohol in People Living With HIV Infection
Brown University
NCT04050735
Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NCT01969058
Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I
Gilead Sciences
NCT02616029
Biomarkers to Predict Time to Plasma HIV RNA Rebound
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NCT03001128
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis
Gilead Sciences
NCT02600819
10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults
David Ho
NCT03875209
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults
Gilead Sciences
NCT03739866
Study of Novel Antiretrovirals in Participants With HIV-1
Gilead Sciences
NCT05585307
Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)
Gilead Sciences
NCT06104306
Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera
Prema Menezes, PhD, PA-C
NCT01701895
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NCT02440789
The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART
University of North Carolina, Chapel Hill
NCT01319383
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
Northwestern University
NCT00993148
Mental Ability Challenge Study in Adults With and Without HIV
Vanderbilt University Medical Center
NCT03244488
A Study of the Safety and Antiretroviral Activity of 3BNC117
Rockefeller University
NCT02588586
Islatravir and Methadone Pharmacokinetics (MK-8591-029)
Merck Sharp & Dohme
NCT04568603
Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV
The University of Texas Health Science Center, Houston
NCT03329560
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 21 |
| Phase 3 | 12 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on HIV-1-infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HIV-1-infection trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HIV-1-infection page
72 registered trials, 24 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 24 HIV-1-infection trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Gilead Sciences sponsors the most HIV-1-infection trials on record, review their full trial history before evaluating a specific study. See Gilead Sciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HIV-1-infection condition card totals 72 registered trials; most-linked intervention B/F/TAF; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.